Do EASL and mRECIST responses have independent effects on survival in hepatocellular carcinoma patients treated with transarterial embolization?

J Hepatol. 2012 Jul;57(1):224-5; author reply 225-6. doi: 10.1016/j.jhep.2012.01.016. Epub 2012 Feb 8.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Carcinoma, Hepatocellular / therapy*
  • Chemoembolization, Therapeutic*
  • Female
  • Humans
  • Liver Neoplasms / therapy*
  • Male